Targeting STAT3 in Breast Cancer Using Innovative Natural andSynthetic Scaffolds to Trigger Apoptosis, Autophagy, and Halt TumorProgression

Targeting STAT3 can be a significant therapeutic strategy, as both synthetic and natural compounds capable of inhibiting STAT3 signaling have been shown in preclinical studies. These findings provide valuable insights for cancer biologists, molecular researchers, and clinicians to explore STAT3 inhibitors as potential breast cancer therapeutics.

Authors

Institutions

Publication Details

Journal
Current Drug Targets
Published
2026-01-07
DOI
https://doi.org/10.2174/0113894501407510251202050624
Primary Topic
Cytokine Signaling Pathways and Interactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Targeting STAT3 in Breast Cancer Using Innovative Natural andSynthetic Scaffolds to Trigger Apoptosis, Autophagy, and Halt TumorProgression

Archana Shivanna, N. A. Rizaeva, Prema Venkatesh, Dilipkumar Reddy Kandula et al.
Current Drug Targets
Cytokine Signaling Pathways and Interactions
article

Targeting STAT3 in Breast Cancer Using Innovative Natural andSynthetic Scaffolds to Trigger Apoptosis, Autophagy, and Halt TumorProgression

Archana Shivanna, N. A. Rizaeva, Prema Venkatesh, Dilipkumar Reddy Kandula, Allaka Nagalakshmi, Bhavana Jayadevappa, Basappa Basappa, Yashwanth Rangaswamy, Harsha Agasimane, Narasimha M. Beeraka, Noureen Usman Sab, Dhanya Dinesh, Vidyashree K. Shivaprakash, Klavdiya Turkandze Amiranova, Thungeshwari C. Paramesh, Chaithra A. Chandru, Syed Hidayathulla, Hemanth Vikram P.R, Ambika H. Devarajanayaka, Padmanabha Reddy Y, Jennifer Anthony, Yashaswi Puttaraju, Anusha H. Krishna, Noortaj J. Subhan
article en

Abstract

Targeting STAT3 can be a significant therapeutic strategy, as both synthetic and natural compounds capable of inhibiting STAT3 signaling have been shown in preclinical studies. These findings provide valuable insights for cancer biologists, molecular researchers, and clinicians to explore STAT3 inhibitors as potential breast cancer therapeutics.

Current Drug TargetsVol. 27
Sechenov University (RU), University of Mysore (IN), Shri Jagdishprasad Jhabarmal Tibrewala University (IN), Jawaharlal Nehru Technological University Anantapur (IN)
Openalex Percentile: Top 94%
Cytokine Signaling Pathways and Interactions
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Targeting STAT3 in Breast Cancer Using Innovative Natural andSynthetic Scaffolds to Trigger Apoptosis, Autophagy, and Halt TumorProgression — Archana Shivanna, N. A. Rizaeva, et al. · Current Drug Targets (2026) | TGRS Research Map | TGRS